 Shares of Global Cord Blood Corp. were up 0.2 in premarket trading on Friday after the Hong Kong-based company said it expects a negative impact to its fourth-quarter performance due to COVID-19, the new coronavirus that has sickened at least 48,000 people, primarily in China. Global Cord Blood, which is an umbilical cord blood banking operator, attribution the projected impact to a combination of factors: some of its workers are not able to return to work due to travel restrictions; hospitals are restricting access to sales representatives, including those employed by Global Cord Blood; and the companys operating costs may rise because it has had to purchase additional medical supplies and equipment for its employees and clients. Global Cord Blood said in a news release that it may adjust its sales target for fiscal 2010 and its strategy for fiscal 2021. The companys stock is down 27 over the past year, while the SP; 500 has gained 22. 